---
schema_version: "secwatch.filing_event.v1"
accession: "0001285550-24-000049"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:35:22.568417+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q1 revenue $7.6M (+41% YoY); biologics revenue $4.3M (+61%); cash burn down 32%

## Summary
- Record quarterly revenue of $7.6M, up 41% YoY; biologics/drug delivery revenue up 61% to $4.3M.
- Capital equipment sales surged 255% to $1.4M; SmartFrame OR received 510(k) clearance and first clinical cases performed.
- Activated 8 new hospital sites in Q1, a company record, bringing total active sites to over 80.
- Operational cash burn reduced 32% to $3.8M; cash and equivalents totaled $35.4M after $16.2M public offering.
- Reaffirmed FY2024 revenue outlook of $28M-$32M; first-ever neuro gene therapy BLA submitted by partner PTC Therapeutics.

## SEC filing metadata
- accession: 0001285550-24-000049
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000128555024000049/0001285550-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000128555024000049/clpt-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001285550-24-000049
- JSON: https://secwatch.observer/filing/0001285550-24-000049.json
- Plain text: https://secwatch.observer/filing/0001285550-24-000049.txt

## Key facts
- Earnings Releases
  ClearPoint Neuro, Inc. reported the first quarter ended March 31, 2024 results: revenue $7.6 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $7.6 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024. First Quarter Highlights • Reported quarterly revenue of $7.6 million, a 41% year-over-year increase; • Increased biologics and drug delivery revenue to $4.3 million, a 61% year-over-year increase; • Partner PTC Therapeutics submitted first-ever
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285550/000128555024000049/0001285550-24-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.